Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Ashley D Hadjis, Griffin W White, Christopher Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Andrew H Matthews, Mary Ellen Martin, Daria V Babushok, Alexander Perl, David L. Porter, Alison W Loren, Keith W Pratz, Selina M Luger, Shannon R McCurdy

Blood (2023) 142 (Supplement 1): 376.

https://doi.org/10.1182/blood-2023-188978

Published: 2023

Journal Articles

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Blood (2023) 142 (Supplement 1): 955.

https://doi.org/10.1182/blood-2023-180185

Published: 2023

Journal Articles

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Blood (2023) 142 (Supplement 1): 217.

https://doi.org/10.1182/blood-2023-182104

Published: 2023

Journal Articles

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Blood (2023) 142 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2023-186978

Published: 2023

Journal Articles

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1022–1024.

https://doi.org/10.1182/blood-2022-168036

Published: 2022

Journal Articles

Fried's Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Cristian C. Taborda, Shannon H Gier, Avery W Stivale, Alexander E. Perl, Saar Gill, Daria V. Babushok, Elizabeth O. Hexner, Noelle V. Frey, Catherine Lai, Ximena Jordan Bruno, Mary Ellen Martin, Ivan Maillard, David L. Porter, Alison W. Loren, Keith W. Pratz, Selina M. Luger, Phyllis A. Gimotty, Shannon R. McCurdy

Blood (2022) 140 (Supplement 1): 10825–10827.

https://doi.org/10.1182/blood-2022-169924

Published: 2022

Journal Articles

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Blood (2021) 138 (Supplement 1): 469.

https://doi.org/10.1182/blood-2021-153955

Published: 2021

Journal Articles

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Janna C. Minehart, Christopher Catania, Linda Perry, Mary Ellen Martin, Jacqueline Smith, Shannon R. McCurdy, Keith W. Pratz, Selina M. Luger, Colleen Timlin, Alexander E. Perl, Mindy Schuster, David L Porter, Alison W. Loren, Elizabeth O. Hexner, Noelle V Frey

Blood (2021) 138 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2021-153920

Published: 2021

Journal Articles

Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia

Andrew Matthews, Alexander E. Perl, Selina M. Luger, Daria V. Babushok, Noelle V Frey, Saar Gill, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, David L. Porter, Edward A. Stadtmauer, Alison W. Loren, Vikram R Paralkar, Ivan Maillard, David Margolis, Keith W. Pratz

Blood (2021) 138 (Supplement 1): 795.

https://doi.org/10.1182/blood-2021-149158

Published: 2021

Journal Articles

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Shannon R. McCurdy, MD, Shannon H. Gier, BS, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Alexander E. Perl, MD, Ivan Maillard, MD PhD, Keith W. Pratz, MD, David L. Porter, MD, Martin P. Carroll, MD, Phyllis A. Gimotty, PhD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 2209.

https://doi.org/10.1182/blood-2019-124468

Published: 2019

Journal Articles

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Mitchell E. Hughes, PharmD, Tracy M. Krause, PharmD, Colleen Timlin, PharmD, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, David L. Porter, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4023.

https://doi.org/10.1182/blood-2018-99-112604

Published: 2018

Journal Articles

Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents

Gee Youn (Geeny) Kim, PharmD, Jonathan Burns, PharmD, Craig W. Freyer, PharmD, Keith Hamilton, MD, Mindy Schuster, MD MSCE, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, David L. Porter, MD, Selina Luger, MD, Alison W. Loren, MD MS

Blood (2018) 132 (Supplement 1): 5512.

https://doi.org/10.1182/blood-2018-99-119168

Published: 2018

Journal Articles

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Colleen Timlin, PharmD, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, Selina Luger, MD, Jacqueline Smith, MSN, CRNP, Edward Stadtmauer, David L. Porter, MD

Blood (2018) 132 (Supplement 1): 5696.

https://doi.org/10.1182/blood-2018-99-111550

Published: 2018

Journal Articles

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Christine M. McMahon, MD, Nya Nelson, MD PhD, Alex Ganetsky, PharmD, James K. Mangan, MD PhD, Noelle V. Frey, MD, Alexander E. Perl, MD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alison W. Loren, MD MS, Elizabeth O. Hexner, MD MS, Adam Bagg, MD, Jennifer J.D. Morrissette, PhD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2018-99-116415

Published: 2018

Journal Articles

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Benjamin M Manning, MD PhD, Robyn T Sussman, PhD, Safoora Deihimi, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, Selina Luger, MD, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Jennifer J.D. Morrissette, PhD, Alexander E. Perl, MD, Edward A. Stadtmauer, MD FACP, David L. Porter, MD, Saar I. Gill, MD PhD

Blood (2018) 132 (Supplement 1): 2134.

https://doi.org/10.1182/blood-2018-99-117410

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old

Christopher C Walling, BS, Pamela A Shaw, PhD, Noelle V Frey, MD, Saar I Gill, MBBS, PhD, Elizabeth O. Hexner, MD, Alison W Loren, MD MS, Selina Luger, MD, James K Mangan, MD PhD, Mary Ellen Martin, MD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, David L. Porter, MD

Blood (2016) 128 (22): 2309.

https://doi.org/10.1182/blood.V128.22.2309.2309

Published: 2016

Journal Articles

A Retrospective Analysis Of The Association Between Common Myeloablative Conditioning Regimens and Hepatotoxicity

Rushang D. Patel, MD, PhD, Thomas R. Klumpp, MD, Mary Ellen Martin, MD, Patricia Kropf, MD, Omotayo O. Fasan, MBBS, Kenneth F. Mangan, MD

Blood (2013) 122 (21): 5515.

https://doi.org/10.1182/blood.V122.21.5515.5515

Published: 2013

Journal Articles

Confirmation of A Strong Relationship Between Race and Probability of Transplant Among Patients Referred for Hematopoietic Cell Transplantation (HCT) for Hematological Maliganancies – A 17 Year Experience

Manish Sharma, MD, Thomas R Klumpp, MD, John A Ulicny, MS, Omotayo O. Fasan, MBBS, Patricia Kropf, MD, Mary Ellen Martin, MD, Kenneth F. Mangan, MD

Blood (2012) 120 (21): 4266.

https://doi.org/10.1182/blood.V120.21.4266.4266

Published: 2012

Journal Articles

Evaluating Trends in Diagnostic and Prognostic Testing for Multiple Myeloma

C. J. Fidler, Ahmed Kamel Abou Hussein, MD, Neel Gandhi, Vinit Karur, MD, Manish Sharma, MD, Thomas R Klumpp, MD, Patricia Kropf, MD, Mary Ellen Martin, MD, Robert V. Emmons, MD, Kenneth F. Mangan, MD

Blood (2011) 118 (21): 2067.

https://doi.org/10.1182/blood.V118.21.2067.2067

Published: 2011

Journal Articles

LACK of ASSOCIATION BETWEEN Race and Probability of TRANSPLANT AMONG PATIENTS Referred for Hematopoietic CELL TRANSPLANTATION (HCT) for MULTIPLE Myeloma

Manish Sharma, MD, Michael Bromberg, MD, PhD, Thomas R. Klumpp, MD, Patricia Kropf, MD, Mary Ellen Martin, MD, Robert V. Emmons, MD, Kenneth F. Mangan, MD

Blood (2011) 118 (21): 3129.

https://doi.org/10.1182/blood.V118.21.3129.3129

Published: 2011

NARROW

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Fried's Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old

A Retrospective Analysis Of The Association Between Common Myeloablative Conditioning Regimens and Hepatotoxicity

Confirmation of A Strong Relationship Between Race and Probability of Transplant Among Patients Referred for Hematopoietic Cell Transplantation (HCT) for Hematological Maliganancies – A 17 Year Experience

Evaluating Trends in Diagnostic and Prognostic Testing for Multiple Myeloma

LACK of ASSOCIATION BETWEEN Race and Probability of TRANSPLANT AMONG PATIENTS Referred for Hematopoietic CELL TRANSPLANTATION (HCT) for MULTIPLE Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only